Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

CSE:RVV - Post by User

Revive Therapeutics Ltd. > Advarra

<< Previous

Bullboard Posts

Next >>

Post by mrnormalon Aug 26, 2020 2:18pm

202 Views

Post# 31456783

Advarra

Advarra Boards meet every Tuesday, Wednesday, and Friday, providing prompt turnaround consistent with other IRB services

https://www.advarra.com/irb-services/

Quote:
Institutional Review Board (IRB) Services Overview
IRB solutions to safeguard research participants
Regardless of your project’s scope, therapeutic niche, or number of investigators, Advarra® is your partner in the conduct of efficient, responsible research. By giving you faster access to information, easier record management, and secure communication tools, Advarra reinforces high-integrity study conduct and regulatory compliance, all while streamlining the way your team communicates.

As the research community’s preferred independent IRB, Advarra offers:

Speed: Reviews of all types of submissions every day, for faster decisions
Flexibility: Convenient electronic tools and dedicated staff for easy, efficient study administration
Accountability: A dedicated point of contact throughout your study
Savings: Early engagement proven to save time and resources in later phase trials